Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or the ‘Company’), a leader in medical imaging using confocal laser endomicroscopy, is pleased to announce its Appendix 4C Quarterly Cashflow report and business update for the quarter ended 31 December 2024 (the ‘Quarter’). All financial results are in Australian dollars and are unaudited.
Highlights for the Quarter
• Product development and clinical pipeline achievements over the Quarter included:
➢ The signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine
➢ The development of a dedicated veterinary imaging product was commenced
➢ The signing of an agreement with Monash University to develop AI technology solutions for gastroenterology imaging
➢ The completion of key CRC-P grant milestones, securing additional $0.398m of funding.
• In a key equipment deliverable, Optiscan provided the first flexible GI scope prototype to University Medical Centre of the Johannes Gutenberg University Mainz for evaluation.
• Substantial progress made on the InVue® product development, with delivery on track to support the clinical evidence generation programs at the Royal Melbourne Hospital and Mayo Clinic.
• Delivery of a ViewnVivo® system to China-based distribution partner following a sale to a large Chinese university; Increased Business Development activities resulted in two ViewnVivo® funding applications in China; Quotes for ViewnVivo® sale issued to two Tier 1 research universities in the US.
• Multiple brand awareness initiatives also occurred over the Quarter including attendance at American College of Veterinary Pathologists and American College of Veterinary Surgeons meetings.
Optiscan’s Chief Executive Officer and Managing Director, Dr. Camile Farah, commented:
“Optiscan enjoyed a highly successful December 2024 quarter, as it continued to advance its core priorities that cut across R&D, commercialization, and market expansion, headlined by the achievement of multiple milestones that position the Company for sustained growth. Key highlights over the Quarter were delivery of our first flexible GI scope prototype to University Medical Centre of the Johannes Gutenberg University Mainz for evaluation and the signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine for veterinary imaging applications. At the same time, our team substantially progressed the Company’s InVue® product development program, delivered a ViewnVivo® system to Chinabased distribution partner, and pulled out all stops to bolster market awareness of Optiscan’s expanding MedTech offering.
These accomplishments reflect our commitment to innovation, not only in addressing immediate market needs but also in laying the foundation for long-term leadership in precision imaging. By focusing on strategic partnerships and transformative technologies, we are building a future where Optiscan’s solutions redefine standards in healthcare and research, delivering lasting value for the medical community, patients, and our shareholders.”
About us:
About Optiscan Imaging
Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.
Using a revolutionary "tissue contact" method, Optiscan’s patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.
The global addressable market for Optiscan’s medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.
To learn more about Optiscan, visit www.optiscan.com
Contact details:
Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
+61 3 9538 3333
[email protected]
Media & Investor Enquiries
The Capital Network
Julia Maguire
+61 2 7257 7338
[email protected]